Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • Hospitals & Diagnostics
    • Manipal-TPG combine...

    Manipal-TPG combine extends validity of revised offer for Fortis

    Written by Ruby Khatun Khatun Published On 2018-05-25T10:40:21+05:30  |  Updated On 25 May 2018 10:40 AM IST
    Manipal-TPG combine extends validity of revised offer for Fortis

    New Delhi: Manipal-TPG combine has said it has extended the validity of its modified offer for Fortis Healthcare to June 6, 2018.


    On May 17, Malaysian firm IHH Healthcare Berhard had extended the acceptance period of its enhanced revised proposal for Fortis to May 29.


    In a letter to the directors of Fortis Healthcare Ltd (FHL), Manipal-TPG combine said it understands that the FHL board is still in the process of considering the modified new offer.


    "As you are aware, our modified new offer is valid till May 29, 2018, and in order to provide the FHL board with sufficient time to consider our modified new offer, we propose to extend the validity of our modified new offer...," the letter added.


    The modified new offer shall remain valid and binding in its entirety until June 6, 2018, for acceptance by FHL Board and for recommendation to the shareholders of FHL, Manipal-TPG combine said.


    The offer shall stand automatically revoked and terminated if it is not accepted by the FHL Board or the company's shareholders within their acceptance period respectively, the letter said.


    Earlier on May 14, Manipal-TPG combine had again sweetened its offer for Fortis at Rs 180 per share, thereby increasing the valuation of the healthcare company to Rs 9,403 crore.


    The combine was the first to make a binding offer for the cash-strapped healthcare chain.


    "For purposes of the merger, a value of Rs 9,403 crore shall be attributed to FHL and a value of Rs 6,070 crore shall be attributed to MHEPL as had been originally determined by the independent valuers for the purpose of the transaction," Manipal Health Enterprises Pvt Ltd (MHEPL) had said in a letter presenting the revised offer.


    It further said: "The preferential allotment shall be undertaken at a price of Rs 180 per share."


    MHEPL claimed that its modified new offer "is significantly better than any other offer/bid FHL has received to date, including the Hero-Burman offer".


    There were five suitors in the race for Fortis, including TPG-Manipal combine, IHH Healthcare and KKR-backed Radiant Life Care, which gave binding offers.


    China's Fosun Healthcare did not make a binding bid for the company.


    IHH Healthcare has extended its revised offer for Fortis till May 29 after which it shall lapse. It had increased its offer to directly invest in Fortis at Rs 175 per share on May 1. It had initially made a non-binding offer to invest in Fortis at Rs 160 per share.

    binding offersextendsFortisFortis HealthcareHero-Burman offerIHHIHH HealthcareKKRManipalMHEPLRadiant Life Carerevised offerTPGvalidity
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok